BP market caps are based on price/earnings, yes, and based on multiple products in a pipeline. This company may well exceed a traditional P/E so you could be right, but when will it ever get to $10b sales in a $39 billion market cap? My original point remains, $79 pps is a $39 billion market cap, half of a mega giant like Gilead. That is fanciful thinking and fun to contemplate but not very likely in the big scheme of biotech. Hey, go for it if that floats your boat. I will not harbor unrealistic expectations, and I have very high expectations here.